BioNTech SE

Yahoo Finance • 3 days ago

Noteworthy ETF Inflows: FNDF, APTV, ZIM, BNTX

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab Fundamental International Large Company Index (Symbol: FNDF) where we have detected an approximate $20... Full story

Yahoo Finance • 4 days ago

RNA-Based Therapeutics & Vaccines Market is projected to reach USD 2.32 Billion by 2032, growing at a CAGR of 5.50% during 2025–2032, Driven by the Rapid Expansion of mRNA Platform Applications: AnalystView Market Insights

San Francisco, USA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The RNA-based Therapeutics and Vaccines Market was valued at USD 1,285.10 million in 2024 and is projected to reach approximately USD 2,320.54 million by 2032, expanding at a CAGR of... Full story

Yahoo Finance • 9 days ago

Moderna sued for violating patent linked to Pfizer/ BioNTech COVID-19 shot

[Moderna To Request Emergency Authorization For Its Vaccine After Positive Trial Results] Maddie Meyer/Getty Images News Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) faces a lawsuit in the U.S. for allegedly infringing patent rig... Full story

Yahoo Finance • 16 days ago

Bristol-Myers Squibb Resets Pipeline With RNA Deals And Cost Focus

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Bristol-Myers Squibb (NYSE:BMY) has outlined a broad pipeline refresh that includes multiple rec... Full story

Yahoo Finance • 3 months ago

Notable healthcare headlines for the week: CVS, Eli Lilly and Novartis in focus

Wall Street's major averages ended lower on Friday, with the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) and the Nasdaq (COMP:IND [https://seekingalpha.com/symbol/COMP:IND]) ending the week in the red as the AI trade came under... Full story

Yahoo Finance • 3 months ago

How Recent Developments Are Rewriting The BioNTech Investment Story

BioNTech's latest narrative update reflects a slightly higher fair value estimate of about $138, tempered by a modestly increased discount rate of roughly 6.72%, as analysts balance confidence in the COVID-19 franchise with more cautious l... Full story

Yahoo Finance • 3 months ago

Moderna (MRNA) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, Aug. 1, 2025 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Stéphane BancelChief Financial Officer — James MockPresident — Stephen Hoge TAKEAWAYS Revenue -- $142 million total, wi... Full story

Yahoo Finance • 3 months ago

China Leads Therapeutic Access with 74 Approved Immuno-Oncology Agents

Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Immuno-oncology (2025)" has been added to ResearchAndMarkets.com's offering. The latest report delves into the dynamic field of immuno-oncology, shedding light on c... Full story

Yahoo Finance • 3 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BioNTech SE Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and sec... Full story

Yahoo Finance • 3 months ago

European Equities Traded in the US as ADRs Little Changed in Monday Trading

European equities traded in the US as American depositary receipts were little changed late Monday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first of two stages of the global Phase 3 tria... Full story

Yahoo Finance • 3 months ago

BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge

Der selektive Treg-Modulatorkandidat Gotistobart (BNT316/ONC-392) zeigte eine Verringerung des Sterberisikos um mehr als die Hälfte im Vergleich zur Standard-Chemotherapie sowie ein kontrollierbares Sicherheitsprofil im ersten von zwei Abs... Full story

Yahoo Finance • 3 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the expiration of the initial offering periodThe su... Full story

Yahoo Finance • 3 months ago

BioNTech erfüllt Mindestannahmebedingungen im Rahmen des Umtauschangebots für CureVac-Aktien

Mindestannahmebedingung für das Angebot wurde erfüllt; es wurden vor Ablauf der ursprünglichen Angebotsfrist insgesamt 184.071.410 CureVac-Aktien angedient, was etwa 81,74 % der ausgegebenen und im Umlauf befindlichen CureVac-Aktien entspr... Full story

Yahoo Finance • 3 months ago

Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10

Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children. Continue Reading View Comments... Full story

Yahoo Finance • 3 months ago

Nvidia's Synopsys investment, Disney stock pops on Zootopia 2

Yahoo Finance host Julie Hyman kicks off Yahoo Finance's Market Minute with some of the top stories of Monday's trading session, including Nvidia's (NVDA) investment in Synopsys (SNPS), Disney's (DIS) "Zootopia 2," and vaccine stock moves.... Full story

Yahoo Finance • 3 months ago

2 Top Dividend Stocks to Buy and Hold

Key Points Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches. These healthcare leaders routinely increase their... Full story

Yahoo Finance • 3 months ago

BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3

[Mature female virologist examining test tube while working in laboratory] Maskot * BioNTech SE (BNTX [https://seekingalpha.com/symbol/BNTX]) on Wednesday announced [https://seekingalpha.com/pr/20320982-biontech-shares-progress-on-excha... Full story

Yahoo Finance • 3 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Offer set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025, due to operational deadlines.Exchange ratio of 0.05363 of a BioNTech Ame... Full story

Yahoo Finance • 3 months ago

BioNTech informiert über Fortschritte im Rahmen des Umtauschangebots für CureVac-Aktien und weist auf Ablauf des Angebots am 3. Dezember 2025 um 15 Uhr MEZ hin

Ablauf des Angebots am 3. Dezember 2025 um 15 Uhr MEZ (9:00 Uhr EST); CureVac-Aktionärinnen und -Aktionären wird empfohlen, ihre Aktien aufgrund operativer Fristen bis spätestens 3. Dezember 2025, 0:00 Uhr MEZ (2. Dezember 2025 um 18:00 Uh... Full story